Almitrine Bismesylate + Raubasine

This tablet is indicated for-

Reduction of neurological damage & accelerates recovery after cerebral stroke

Minor age-related neurological disorders

Some visual disorders related to the circulation

Some disorders of the inner ear related to circulation (hearing loss, dizziness, buzzing sounds in the ear).

Almitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa0 2 ); almitrine causes an increase in the Pa0 2 and an increase in the oxygen saturation in arterial blood (Sa0 2 ), without modifying ventilatory parameters.

1 tablet once or twice daily (taken separately, several hours apart), without exceeding 2 tablets per day. Or, as directed by the registered physicians.

Do not associate with MAO-l (monoamine oxidase inhibitor), Not to be used concurrently with other almitrine-containing preparations.

This tablet is contraindicated in patients with hypersensitivity to any of the ingredients of it or severe hepatic impairment.

Weight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations.

It is not recommended in pregnancy. It should be used with caution only when the expected benefit to the mother is greater than the possible risk to the fetus.

Due to the presence of lactose, Albasine should not be used in the case of galactosemia, of glucose and galactose malabsorption syndrome or of lactose deficiency (rare metabolic diseases). Do not exceed the recommended dose.

Signs include tachycardia, arterial hypotension, polypnoea and respiratory alkalosis.

Store at a cool and dry place, protected from light and moisture. Keep out of reach of children.